Medical Research Council (MRC), Uganda Virus Research Institute (UVRI), Uganda Research Unit on AIDS, Entebbe, Uganda.
PLoS One. 2011;6(6):e20684. doi: 10.1371/journal.pone.0020684. Epub 2011 Jun 3.
Local HIV epidemiology data are critical in determining the suitability of a population for HIV vaccine efficacy trials. The objective of this study was to estimate the prevalence and incidence of, and determine risk factors for HIV transmission in a rural community-based HIV vaccine preparedness cohort in Masaka, Uganda.
Between February and July 2004, we conducted a house-to-house HIV sero-prevalence survey among consenting individuals aged 18-60 years. Participants were interviewed, counseled and asked to provide blood for HIV testing. We then enrolled the HIV uninfected participants in a 2-year HIV sero-incidence study. Medical evaluations, HIV counseling and testing, and sample collection for laboratory analysis were done quarterly. Sexual risk behaviour data was collected every 6 months.
The HIV point prevalence was 11.2%, and was higher among women than men (12.9% vs. 8.6%, P = 0.007). Risk factors associated with prevalent HIV infection for men were age <25 years (aOR = 0.05, 95% CI 0.01-0.35) and reported genital ulcer disease in the past year (aOR = 2.17, 95% CI 1.23-3.83). Among women, being unmarried (aOR = 2.59, 95% CI 1.75-3.83) and reported genital ulcer disease in the past year (aOR = 2.40, 95% CI 1.64-3.51) were associated with prevalent HIV infection. Twenty-one seroconversions were recorded over 2025.8 person-years, an annual HIV incidence of 1.04% (95% CI: 0.68-1.59). The only significant risk factor for incident HIV infection was being unmarried (aRR = 3.44, 95% CI 1.43-8.28). Cohort retention after 2 years was 87%.
We found a high prevalence but low incidence of HIV in this cohort. HIV vaccine efficacy trials in this population may not be feasible due to the large sample sizes that would be required. HIV vaccine preparatory efforts in this setting should include identification of higher risk populations.
了解当地艾滋病病毒(HIV)的流行情况对于确定人群是否适合进行 HIV 疫苗功效试验至关重要。本研究旨在评估乌干达马萨卡市一个农村社区 HIV 疫苗准备队列中 HIV 的流行率、发病率以及 HIV 传播的危险因素。
在 2004 年 2 月至 7 月期间,我们对同意参加的 18-60 岁人群进行了一次逐户 HIV 血清流行率调查。对参与者进行访谈、咨询,并要求其提供血液进行 HIV 检测。然后,我们将未感染 HIV 的参与者纳入为期 2 年的 HIV 血清发病率研究。每季度进行医学评估、HIV 咨询和检测以及实验室分析样本采集。每 6 个月收集一次性行为风险数据。
HIV 现患率为 11.2%,女性高于男性(12.9% vs. 8.6%,P = 0.007)。与男性现患 HIV 感染相关的危险因素为年龄<25 岁(调整比值比[aOR]为 0.05,95%置信区间[CI]为 0.01-0.35)和过去一年有生殖器溃疡病(aOR 为 2.17,95% CI 为 1.23-3.83)。在女性中,未婚(aOR 为 2.59,95% CI 为 1.75-3.83)和过去一年有生殖器溃疡病(aOR 为 2.40,95% CI 为 1.64-3.51)与现患 HIV 感染相关。在 2025.8 人年中记录了 21 例血清转换,年 HIV 发病率为 1.04%(95%CI:0.68-1.59)。唯一与新发 HIV 感染相关的显著危险因素是未婚(调整发病比[aRR]为 3.44,95% CI 为 1.43-8.28)。2 年后的队列保留率为 87%。
我们发现该队列中 HIV 的流行率较高,但发病率较低。由于需要较大的样本量,该人群的 HIV 疫苗功效试验可能不可行。在这种情况下,HIV 疫苗准备工作应包括确定高危人群。